RadNet (RDNT) Aandelenoverzicht
RadNet, Inc. biedt samen met haar dochterondernemingen poliklinische diagnostische beeldvormingsdiensten aan in de Verenigde Staten en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
RDNT Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
RadNet, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$76.82 |
| 52 Week Hoogtepunt | US$85.84 |
| 52 Week Laag | US$50.82 |
| Bèta | 1.38 |
| 1 maand verandering | 29.72% |
| 3 maanden verandering | 41.21% |
| 1 Jaar Verandering | 9.59% |
| 3 jaar verandering | 139.31% |
| 5 jaar verandering | 147.17% |
| Verandering sinds IPO | 7,582.00% |
Recent nieuws en updates
Seeking Alpha • Aug 12
RadNet: Imaging And AI Keep The Bull Case Intact
Summary RDNT's advanced imaging mix is expanding. I think this will continue to support its improving revenue quality and margins. RDNT's joint ventures across healthcare systems also help it deepen its integration across customers' workflows. DeepHealth is RDNT's second growth leg, as it pairs external software sales with internal workflow efficiencies. Gleamer also creates more opportunities to monetize AI across RDNT's own imaging solutions portfolio. As such, I think RDNT still looks quite compelling, especially if you're a long-term bull in this rapidly growing healthcare niche. Read the full article on Seeking Alpha
Nieuw narratief • Aug 12
AI And Advanced Imaging Will Drive Stronger Margins And Earnings Durability
Catalysts About RadNet RadNet operates a large network of outpatient imaging centers and a growing digital health platform focused on radiology AI and enterprise imaging software. What are the underlying business or industry changes driving this perspective?
Narratiefupdate • Aug 11
RDNT: Imaging Expansion And Breast Ultrasound AI Clearance Will Support Earnings
Analysts have increased their RadNet fair value estimate from $89.75 to $92.88, citing higher price targets supported by recent revenue and adjusted EBITDA beats, stronger imaging center trends reflected in raised FY26 guidance, and additional upside potential from the FDA clearance for the DeepHealth breast ultrasound AI solution. Analyst Commentary Recent research on RadNet highlights a mix of optimism on execution and growth, alongside a few valuation and competitive questions that investors should keep in mind.Recent updates
Seeking Alpha • Aug 12
RadNet: Imaging And AI Keep The Bull Case Intact
Summary RDNT's advanced imaging mix is expanding. I think this will continue to support its improving revenue quality and margins. RDNT's joint ventures across healthcare systems also help it deepen its integration across customers' workflows. DeepHealth is RDNT's second growth leg, as it pairs external software sales with internal workflow efficiencies. Gleamer also creates more opportunities to monetize AI across RDNT's own imaging solutions portfolio. As such, I think RDNT still looks quite compelling, especially if you're a long-term bull in this rapidly growing healthcare niche. Read the full article on Seeking AlphaNieuw narratief • Aug 12
AI And Advanced Imaging Will Drive Stronger Margins And Earnings Durability
Catalysts About RadNet RadNet operates a large network of outpatient imaging centers and a growing digital health platform focused on radiology AI and enterprise imaging software. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Aug 11
RDNT: Imaging Expansion And Breast Ultrasound AI Clearance Will Support Earnings
Analysts have increased their RadNet fair value estimate from $89.75 to $92.88, citing higher price targets supported by recent revenue and adjusted EBITDA beats, stronger imaging center trends reflected in raised FY26 guidance, and additional upside potential from the FDA clearance for the DeepHealth breast ultrasound AI solution. Analyst Commentary Recent research on RadNet highlights a mix of optimism on execution and growth, alongside a few valuation and competitive questions that investors should keep in mind.Narratiefupdate • Jun 24
RDNT: Advanced Imaging And AI Platform Expansion Will Support Future Earnings
RadNet's analyst price target has shifted lower by $5 to $65, with analysts pointing to both the recent target cuts from Barclays and B. Riley and ongoing confidence reflected in its inclusion on Jefferies' Franchise Picks list as key context for the revision.Narratiefupdate • Jun 06
RDNT: Advanced Imaging And AI Execution Will Support Future Earnings
Narrative Update: RadNet The updated analyst price target for RadNet has shifted modestly lower to around $90 per share. This reflects analysts’ recalibration of fair value and discount rate assumptions, while also acknowledging continuing support from recent research that highlights the stock’s inclusion in high-conviction lists and its relative strength in advanced volume growth and imaging pricing versus peers.Analyse-artikel • May 14
Analysts Have Made A Financial Statement On RadNet, Inc.'s (NASDAQ:RDNT) First-Quarter Report
Last week, you might have seen that RadNet, Inc. ( NASDAQ:RDNT ) released its quarterly result to the market. The early...Narratiefupdate • May 07
RDNT: Imaging Platform Execution And New Idaho Venture Will Support Future Earnings
Analysts have trimmed their fair value estimate for RadNet by $0.50 to $89.88, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E after recent Street research, including a lower $4 price target from B. Riley and an upgrade of Lumexa Imaging at Raymond James.Narratiefupdate • Apr 23
RDNT: Sector Sentiment Tailwinds Will Support Future Earnings Visibility
Analysts have trimmed their price target on RadNet by $2 to reflect slightly updated assumptions on fair value, future P/E and operating metrics, while incorporating recent Street research that highlights improved sentiment following the Raymond James upgrade of Lumexa Imaging. Analyst Commentary Bullish Takeaways Bullish analysts view the recent upgrade of Lumexa Imaging as a supportive read-through for sentiment around diagnostic imaging.Narratiefupdate • Apr 08
RDNT: Outpatient Imaging Shift Will Support Future Earnings Visibility
RadNet's analyst price target now stands at $92. Analysts cite outpatient diagnostic imaging growth drivers, Medicare reimbursement support, potential capital deployment, and an AI ramp as key reasons for maintaining this level.Narratiefupdate • Mar 25
RDNT: Outpatient Imaging Shift And AI Adoption Will Drive Future Upside
Analysts kept their $92 price target for RadNet unchanged, citing what they see as attractive long term growth drivers in outpatient diagnostic imaging, reasonable 2025 to 2028 company targets, supportive Medicare reimbursement trends, potential capital deployment benefits, and expected AI contributions. Analyst Commentary Bullish Takeaways Bullish analysts view outpatient diagnostic imaging as an attractive subsector, with hospital to outpatient shifts and growing demand for advanced imaging seen as key growth drivers that support RadNet's long term story and current valuation framework.Narratiefupdate • Mar 09
RDNT: Outpatient Imaging Shift And AI Ramp Will Support Future Upside
Analysts have raised their price target on RadNet from $91.75 to $92.38. The updated target reflects revised assumptions that incorporate higher projected revenue growth, a lower profit margin outlook, and a higher future P/E multiple supported by recent bullish Street research on outpatient imaging and AI benefits.Narratiefupdate • Feb 22
RDNT: Outpatient Imaging Shift And AI Adoption Will Support Future Upside
Analysts have trimmed their implied future P/E assumption for RadNet, leading to a slightly lower blended price target of about $97 vs. roughly $102 previously.Narratiefupdate • Feb 08
RDNT: Outpatient Imaging Shift And AI Breast Screening Will Support Upside
Analysts have raised their price target on RadNet to about $92, reflecting confidence in the outpatient diagnostic imaging segment and the company's 2025 to 2028 targets, including expected benefits from improved Medicare rates, potential capital deployment, and increasing AI contributions. Analyst Commentary Recent research reflects a generally constructive tone on RadNet, with several firms lifting price targets into the high US$80s to low US$90s range and highlighting both the core imaging business and longer term AI potential.Narratiefupdate • Jan 24
RDNT: Outpatient Imaging Shift And AI Breast Screening Will Drive Upside
Analysts lifted their price target on RadNet to about US$91.75 from roughly US$91.71, reflecting recent coverage that highlights outpatient imaging growth drivers, supportive Medicare reimbursement, capital deployment options, and potential contributions from artificial intelligence (AI). Analyst Commentary Recent Street research on RadNet focuses on outpatient imaging growth, long term targets and the role of AI and capital allocation in supporting the current valuation framework.Narratiefupdate • Jan 09
RDNT: Outpatient Imaging And AI Adoption Will Drive Future Outperformance
Analysts have raised their price target on RadNet to about US$92, citing what they view as reasonable 2025 to 2028 goals, supportive Medicare reimbursement trends, potential capital deployment upside, and growing contributions from AI and outpatient imaging demand. Analyst Commentary Recent research has focused on how RadNet's outpatient imaging footprint, AI initiatives, and long term financial targets could support its valuation and growth ambitions.Narratiefupdate • Dec 13
RDNT: Integrated Offerings And Margin Expansion Will Drive Future Outperformance
Analysts have modestly increased their price target on RadNet, citing stronger long term growth and margin expansion prospects highlighted at the recent investor day and reflected in updated fair value estimates rising from about $91.71 to roughly $92.50 per share, alongside reaffirmed expectations for double digit revenue growth and mid teens EBITDA expansion. Analyst Commentary Bullish analysts highlight that the updated 2028 targets for double digit revenue growth and margin expansion underpin a durable mid teens EBITDA growth profile, which they view as supportive of further multiple expansion from current levels.Narratiefupdate • Nov 28
RDNT: Sustained Demand And Integrated Offerings Will Drive Future Outperformance
Analysts have raised their price target for RadNet from approximately $87 to $93, citing higher revenue growth expectations and confidence in the company’s integrated offerings and sustained demand. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for RadNet, citing encouraging revenue growth expectations and confidence in the company’s ability to deliver sustained margin expansion.Analyse-artikel • Nov 14
Earnings Miss: RadNet, Inc. Missed EPS By 65% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that RadNet, Inc. ( NASDAQ:RDNT ) filed its third-quarter result this time last week...Narratiefupdate • Nov 13
RDNT: Momentum Will Accelerate From Surging Demand And Integrated Offerings
RadNet’s analyst price target has increased from $80.57 to $86.67. This reflects confidence from analysts who cite strong demand, integrated offerings, and positive industry momentum as key drivers.Narratiefupdate • Oct 30
RDNT: Imaging Center Demand And Digital Health Will Drive Measured Upside Potential
Analysts have increased their price target for RadNet from $74 to $81. They cite strong core imaging center demand and ongoing investments in digital health as key factors for the optimistic outlook.Narratiefupdate • Oct 15
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
RadNet's analyst price target has been raised from $79.29 to $80.57 per share. This change reflects analysts' optimism amid strong imaging center demand, ongoing digital health investments, and potential M&A opportunities.Narratiefupdate • Sep 19
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
RadNet’s consensus price target has risen to $79.29 as analysts cite robust imaging center demand, expanding service opportunities, strong digital health investments, and confidence in management’s strategic execution. Analyst Commentary Robust core imaging center demand trends indicate sustained growth potential.Analyse-artikel • Sep 12
RadNet (NASDAQ:RDNT) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Narratiefupdate • Sep 04
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
Driven by robust imaging center demand, growth opportunities, and strong digital health investments, RadNet’s consensus analyst price target held steady at $77.43. Analyst Commentary Robust core imaging center demand trends highlighted in recent management meetings.Seeking Alpha • Mar 11
RadNet: On The Sidelines For Now
Summary RDNT's stock performance has been lackluster, with only an 8.8% increase over the past year, currently trading at $50 per share. Despite decent fundamentals, including steady revenue growth and strong operating cash flow, RDNT faces risks from wage increases and weather-related disruptions. Recent market overreaction to temporary weather impacts presents a potential rebound opportunity, but the projected 8.6% return does not justify the investment risk. I rate RDNT as neutral due to uncertainties in revenue growth and bottom-line pressures, suggesting better opportunities elsewhere with more favorable risk-reward profiles. Read the full article on Seeking AlphaSeeking Alpha • Oct 02
RadNet: Secular Tailwinds Underpinned By AI Monetization Prospects
Summary RadNet, the largest US diagnostic imaging operator, projects $1.8bn in 2024 revenue, driven by AI and Digital Health growth, and expanding imaging centers. Strong Q2 results with 13.9% revenue growth and 19.7% EBITDA increase, fueled by AI advancements and new imaging center openings. Future growth catalysts include market shifts to freestanding centers, increasing importance of joint ventures, and capital deployment for acquisitions and new facilities. Digital Health and AI initiatives, like DeepHealth OS and EBCD, are expected to drive significant revenue and margin expansion. Read the full article on Seeking Alpha
Nieuw narratief • Aug 30
Expanding Imaging Modalities And AI Integration Signal Strong Future Growth In Healthcare Sector
Expansion into advanced imaging and integration of AI technologies aim at boosting revenue through higher reimbursement rates and operational efficiencies.Seeking Alpha • Aug 24
RadNet: Growth In Operating Earnings Off Very Little Incremental Capital
Summary RDNT stock is up 10% since my June publication following a strong set of quarterly numbers in its Q2 FY'24 earnings. Management continue executing on the growth route, recycling funds into new store openings. Same-store procedure volumes continue to ratchet higher, evidencing increased utilization of its legacy base. Net-net, reiterate buy. Read the full article on Seeking AlphaSeeking Alpha • Jun 05
RadNet: Qualified Growth Route, Still Undervalued
Summary RadNet, Inc. shares continue to show strength, having compounded by 184% since 2022. Q1 FY 2024 earnings showed growth in the Digital Health segment and increased MRI, CT, and PET/CT volumes. Management has increased its outlook on full-year revenues and projects $1.67-$1.7 billion in revenue for the year. Read the full article on Seeking AlphaSeeking Alpha • Jan 28
RadNet, Inc. Stock Price Is More Vigorous Than Its Valuation
Summary RadNet, Inc. is assessed as a Buy opportunity especially on price dips for retail value investors; watch its valuation and growth ratings. The company's share price has seen significant growth recently but may drop due to volatility and potential missed estimates. RadNet is at the forefront of the movement to bring diagnostic imaging services out of hospitals, offering lower costs and increased accessibility. Read the full article on Seeking AlphaRendement voor aandeelhouders
| RDNT | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | 0.6% | -1.5% | -1.5% |
| 1Y | 9.6% | 23.2% | 17.9% |
Rendement versus industrie: RDNT presteerde slechter dan de US Healthcare -sector, die het afgelopen jaar een rendement van 23.2 % opleverde.
Rendement versus markt: RDNT presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 17.9 % opleverde.
Prijsvolatiliteit
| RDNT volatility | |
|---|---|
| RDNT Average Weekly Movement | 6.3% |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: RDNT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van RDNT is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1981 | 9,060 | Howard Berger | www.radnet.com |
RadNet, Inc. biedt samen met haar dochterondernemingen poliklinische diagnostische beeldvormingsdiensten aan in de Verenigde Staten en internationaal. Het bedrijf is actief in twee segmenten, Imaging Centers en Digital Health. De diensten van het bedrijf omvatten magnetische resonantiebeeldvorming, computertomografie, positronemissietomografie, nucleaire geneeskunde, mammografie, echografie, diagnostische radiologie, fluoroscopie en andere gerelateerde procedures, evenals multimodale beeldvormingsdiensten.
RadNet, Inc. Samenvatting
| RDNT fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$6.06b |
| Inkomsten(TTM) | -US$21.12m |
| Inkomsten(TTM) | US$2.27b |
2.7x
P/S-verhouding-286.3x
Koers/WinstverhoudingIs RDNT overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| RDNT resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$2.27b |
| Kosten van inkomsten | US$1.88b |
| Brutowinst | US$392.17m |
| Overige uitgaven | US$413.28m |
| Inkomsten | -US$21.12m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.27 |
| Brutomarge | 17.28% |
| Nettowinstmarge | -0.93% |
| Schuld/Eigen Vermogen Verhouding | 95.6% |
Hoe presteerde RDNT op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/21 23:17 |
| Aandelenkoers aan het einde van de dag | 2026/08/21 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
RadNet, Inc. wordt gevolgd door 12 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Sarah James | Barclays |
| Andrew Mok | Barclays |
| Yuan Zhi | B. Riley Securities, Inc. |